NEW YORK--(BUSINESS WIRE)--Enzo Biochem, Inc. (NYSE:ENZ), a leading biotechnology company specializing in gene identification and genetic and immune regulation technologies for diagnostic and therapeutic applications, announced today that Barry Weiner, President, and David Goldberg, Vice President, Corporate Development, will both be presenting at two upcoming institutional investor conferences:
